News and Announcements
Oncosil Medical Group (ASX:OSL) Annual Update 2015; Shares Up Over 182%
- Published January 05, 2016 2:42PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
2015 Highlights:
- Share price up 182.35%
- Completed the granted Fast Track review by the European regulator Conformité Européenne
- International life sciences research group, Van Leeuwenhoeck Institute, initiated an analyst research coverage on the Company
- Multiple new Board Appointments
OncoSil™ is a patent protected proprietary medical device (class III) that creates a localised stream of beta radiation. The product is created by melting up to 5% phosphorous in liquid silicon in a furnace which is then shattered into small particles using sterile water. The resulting radioactive phosphorous (P32) produces radioactive beta particles that can be emitted for up to three months.
Patients with unresectable pancreatic cancer have few treatment options. The current standard of care is to provide intravenous chemotherapy, and in some cases external beam radiation. The OncoSil™ is intended to complement existing standard of care chemotherapy.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
